$110M Private Placement Fuels Climb Bio’s Immune Disease Pipeline
Event summary
- $110M private placement closed on April 29, 2026 with institutional investors including Adage Capital and RA Capital Management.
- 9.5M shares sold at $9.50 per share plus pre-funded warrants for additional 2.1M shares.
- Proceeds to support development of budoprutug (anti-CD19) and CLYM116 (anti-APRIL) for immune-mediated diseases.
The big picture
This $110M private placement represents a strategic cash infusion for Climb Bio as it advances two key therapeutic candidates. The participation of major healthcare-focused investors underscores confidence in the immune-mediated disease market, particularly for novel monoclonal antibodies targeting B-cell and APRIL pathways. The financing comes at a critical juncture where clinical-stage biotechs must demonstrate both scientific progress and financial runway to attract future investment.
What we're watching
- Pipeline Execution
- How Climb Bio will allocate proceeds between budoprutug and CLYM116 development timelines.
- Market Positioning
- Whether $110M is sufficient to compete with larger players in immune-mediated disease space.
- Investor Confidence
- The pace at which new institutional investors will engage following this financing round.
Related topics